Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. Click the below to access the fill Forbes article.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
read more
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more
Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more
- © UX Strategy & Digital Branding
